With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.
1-(3-Methoxy-4-propoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione (compound 126, FIG. 5) 3,4,5-Trimethoxyphenylvinylketone (11.6 g, 0.052 mol), 3-methoxy-4-propoxy-5-iodobenzaldehyde (13.8 g, 0.043 mol), and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (4.6 g. 0.017 mol) were stirred in trimethylamine (35 mL) at 60¡ã C. for 16 hours. The solution was then acidified, poured into chloroform (500 mL) and washed with 10percent HCl, water and saturated aqueous sodium chloride. The organic layer was dried over magnesium sulfate, concentrated under reduced pressure, and the product isolated from petroleum ether-ethyl acetate to provide pale yellow microcrystals (27 g, 92percent), m.p. 119¡ã-121¡ã C. 1 H NMR (CDCl3) 1.07 (t, 3 H), 1.86 (m, 2 H), 3.40 (dd, 4H), 3.88 (s, 3H), 3.92 (s, 9H), 4.04 (t, 2 H), 7.29 (d, 1 H), 8.07 (d, 1 H).
4568-71-2, As the paragraph descriping shows that 4568-71-2 is playing an increasingly important role.
Reference£º
Patent; CytoMed, Inc.; US5358938; (1994); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI